88 related articles for article (PubMed ID: 3966808)
1. [Changes of immunosuppressive acidic protein (IAP) in patients treated with total-body hyperthermia].
Maeta M; Koga S; Shimizu N; Yoshioka H; Wakatsuki T
Gan To Kagaku Ryoho; 1985 Jan; 12(1):163-5. PubMed ID: 3966808
[No Abstract] [Full Text] [Related]
2. [Immunosuppressive factor in the sera of patients with stomach cancer--with special reference to IAP (immunosuppressive acidic protein)].
Shimizu N; Izumi A; Ozaki Y; Kanayama H; Maeda M; Koga S
Gan No Rinsho; 1982; 28(2):125-8. PubMed ID: 7182557
[No Abstract] [Full Text] [Related]
3. Erythrocyte osmotic fragility in patients receiving hyperthermia with and without chemotherapy.
Whang-Peng J; Lees DE; Schuette WH; Smith R; Bull JM; DeVita VT
Cancer Treat Rep; 1981; 65(11-12):1103-4. PubMed ID: 7296555
[TBL] [Abstract][Full Text] [Related]
4. [Clinical evaluation of the serum level of immunosuppressive acidic protein (IAP) and immunosuppressive substance (IS) in gastric cancer patients].
Sakita M; Yamane T; Kasuga M; Torii T; Imai H; Kageyama N; Fujita Y; Majima S
Gan To Kagaku Ryoho; 1982 Oct; 9(10):1755-64. PubMed ID: 7184372
[TBL] [Abstract][Full Text] [Related]
5. [TA90--new neoplastic marker].
Rudzki S; Gołyski J; Bronikowski P; Gołyska D
Pol Merkur Lekarski; 2010 Mar; 28(165):211-3. PubMed ID: 20815170
[TBL] [Abstract][Full Text] [Related]
6. [The relationship between serum immunosuppressive acidic protein (IAP) and cellular immunity in the patients with gastric cancer].
Nakanishi K; Toge T; Hamamoto S; Tanada M; Itagaki E; Kohno H; Yanagawa E; Hattori T
Gan To Kagaku Ryoho; 1982 Oct; 9(10):1827-31. PubMed ID: 6223588
[TBL] [Abstract][Full Text] [Related]
7. Gc group distributions in patients with cancer.
Hughes NR
J Natl Cancer Inst; 1968 Aug; 41(2):303-11. PubMed ID: 4299536
[No Abstract] [Full Text] [Related]
8. [Immunosuppressive acidic glycoprotein (IAP) and immunosuppressive substance].
Ogoshi K; Kondoh Y; Nakasaki H; Tajima T; Mitomi T
Gan No Rinsho; 1983 Aug; 29(9):987-90. PubMed ID: 6688640
[TBL] [Abstract][Full Text] [Related]
9. [Extracorporeal systemic hyperthermia and cis-diamminedichloroplatinum for treatment of patients with advanced cancer].
Yokoyama M; Wada J; Nagara H; Kasagi Y; Itaoka T
Gan To Kagaku Ryoho; 1984 Jul; 11(7):1457-61. PubMed ID: 6540070
[TBL] [Abstract][Full Text] [Related]
10. [Effect of whole-body artificial hyperthermia on the immunity function in cancer patients].
Dzhaginian AI; Balliuzek FV
Vopr Onkol; 1984; 30(5):39-43. PubMed ID: 6730415
[TBL] [Abstract][Full Text] [Related]
11. [Determination of urinary immunosuppressive acidic protein in cancer patients].
Hirayama T; Tamura K; Kikuchi S; Shibata Y; Kanno H; Sato Y; Ishida N; Kikuchi K
Gan No Rinsho; 1983 Sep; 29(11):1323-9. PubMed ID: 6685196
[TBL] [Abstract][Full Text] [Related]
12. Comparison of S100 protein and MIA protein as serum marker for malignant melanoma.
Djukanovic D; Hofmann U; Sucker A; Rittgen W; Schadendorf D
Anticancer Res; 2000; 20(3B):2203-7. PubMed ID: 10928178
[TBL] [Abstract][Full Text] [Related]
13. [Evaluation of biochemical reactions in the diagnosis of tumors of the abdominal cavity].
Dziubko NIa; Alferov AN; Dumbadze ND
Vopr Onkol; 1973; 19(6):34-8. PubMed ID: 4360327
[No Abstract] [Full Text] [Related]
14. Serum immunosuppressive acidic protein in patients with carcinoma of the gastrointestinal tract particularly the stomach.
Kageyama T; Oyabu H; Ohshiba S
Bull Osaka Med Sch; 1986 Jul; 32(1):32-40. PubMed ID: 3651631
[No Abstract] [Full Text] [Related]
15. MIA, a novel serum marker for progression of malignant melanoma.
Bosserhoff AK; Lederer M; Kaufmann M; Hein R; Stolz W; Apfel R; Bogdahn U; Buettner R
Anticancer Res; 1999; 19(4A):2691-3. PubMed ID: 10470221
[TBL] [Abstract][Full Text] [Related]
16. [Changes in serum proteins in nude mice with human carcinomas and mouse sarcoma].
Takahashi T; Takami H; Sadahiro S; Okuda K; Yamataka K; Kodaira S; Abe O; Manabe T; Takahashi Y; Okuyama T
Nihon Gan Chiryo Gakkai Shi; 1986 Aug; 21(7):1369-75. PubMed ID: 3782982
[No Abstract] [Full Text] [Related]
17. Prognostic value of preoperative immunosuppressive acidic protein levels in patients with gastric carcinoma.
Takeuchi H; Maehara Y; Tokunaga E; Koga T; Kakeji Y; Sugimachi K
Hepatogastroenterology; 2003; 50(49):289-92. PubMed ID: 12630043
[TBL] [Abstract][Full Text] [Related]
18. [S-100B and MIA (melanoma inhibiting activity) serum proteins: a prospective study of their value as melanoma progression markers].
Dornier C; Dousset B; Legras B; Barbaud A; Schmutz JL
Ann Dermatol Venereol; 2002 May; 129(5 Pt 1):739-40. PubMed ID: 12124520
[No Abstract] [Full Text] [Related]
19. [Effect of bestatin on immuno-suppressive acidic protein in patients with stomach cancer].
Ishii T; Takeshita K; Sunagawa M; Habu H; Hoshi K
Gan To Kagaku Ryoho; 1984 Aug; 11(8):1585-90. PubMed ID: 6476836
[TBL] [Abstract][Full Text] [Related]
20. Serum values of tumour necrosis factor-alpha and of soluble tumour necrosis factor-R55 in melanoma patients.
Ocvirk J; Stabuc B; Rudolf Z; Galvani V; Curin-Serbec V
Melanoma Res; 2000 Jun; 10(3):253-8. PubMed ID: 10890379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
